报价延迟最少15分钟:2026/05/19 02:40 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
566.99 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
27.05/35.38
|
|
企业价值
24.43B
|
| 资产负债 |
|
每股账面净值
139.02
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
3.18B
|
|
每股收益
51.93
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United Statesand Rest of the World, of which United States generates majority of the revenue. |
